title: A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer.
abstract: BACKGROUND
  The assessment of bone metastases by clinical examination or imaging techniques is still considered unreliable. We compared a specific marker of bone resorption, urinary deoxypyridinoline (DPD)-crosslinks, with serum calcium (Ca), alkaline phosphatase (AP) and CA27.29, to evaluate the status of bone metastases in patients with breast cancer.
  
  
  METHODS
  Second morning voided urine was collected from 2 groups of patient (pts), those without evidence of disease (n = 118), and those with bone metastases (n = 85) under specific therapy plus pamidronate. DPD and CA27.29 were measured on the automated ACS180 system (Bayer Diagnostics, Tarrytown, NY, USA). Receiver operating characteristics (ROC) curves were established for each of the 4 biomarkers to determine whether they could distinguish the 2 subsets of pts with clinically sufficient validity, and to establish the corresponding cut-off values.
  
  
  RESULTS
  Neither Ca nor AP was useful in discriminating the 2 subgroups. At a DPD cut-off of 13 nmol/mmol, we found a specificity of 69% and a sensitivity of 53% for diagnosing bone metastases. Best results, however, were seen for CA27.29. A cut-off value of 30 U/ml resulted in a specificity of 62% and a sensitivity of 81%.
  
  
  CONCLUSIONS
  CA27.29 was the best parameter for the discrimination of stage IV breast cancer with bone metastases. The primary advantage of DPD lies in the monitoring of bone metastases under specific therapy.
authors.affiliation: Medizinische Klinik und Poliklinik II, Schwerpunkt Onkologie und Hämatologie, Universitätsklinikum Charité, Campus Mitte, Schumannstr. 20-21, 10117 Berlin, Germany. Diana.Lueftner@rz.hu-berlin.de
authors.forename: D
authors.initials: D
authors.lastname: Lüfter
authors.forename: A
authors.initials: A
authors.lastname: Richter
authors.forename: S
authors.initials: S
authors.lastname: Günther
authors.forename: B
authors.initials: B
authors.lastname: Flath
authors.forename: C
authors.initials: C
authors.lastname: Akrivakis
authors.forename: R
authors.initials: R
authors.lastname: Geppert
authors.forename: K D
authors.initials: KD
authors.lastname: Wernecke
authors.forename: K
authors.initials: K
authors.lastname: Possinger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D001859:Bone Neoplasms / Q000097:blood* / Q000188:drug therapy; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D000970:Antineoplastic Agents; D015415:Biomarkers; C090797:CA 27-29 antigen